New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:05 EDTAGIOAgios Pharmaceuticals announces AG-221 orphan drug designation
Agios Pharmaceuticals announced that the U.S. Food and Drug Administration has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia. AG-221 is an oral IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
News For AGIO From The Last 14 Days
Check below for free stories on AGIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AGIO

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use